



To: DRUGSCAN and DSI Customers

From: Anthony G. Costantino, PhD, F-ABFT, President, DRUGSCAN
Brian Wright, President, ACM Global Laboratories

Subject: COVID-19 Readiness: DRUGSCAN and DSI Response to COVID-19

Date: Friday, March 13, 2020

As the novel coronavirus (COVID-19) continues to spread in the U.S. and across the globe, I want to take a moment to let you know what ACM Global Laboratories including DRUGSCAN/DSI is doing to respond to this public health emergency.

First and foremost, DRUGSCAN/DSI's number one priority is the safety and well-being of our people, clients, families, and the communities in which we live and work.

We've assembled an executive level dedicated global COVID-19 Task Force (GCTF) to continually monitor the COVID-19 public health emergency and to put measures in place that help ensure both safety for our people and business continuity for our clients.

We are assessing the situation in real-time, remaining vigilant, and following all recommendations from the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC) and local authorities.

We continue to develop, update, and share guidance with our professionals so they are fully informed on how to protect themselves, their families and their clients against transmission of the virus as this situation evolves.

Please be assured that while we remain focused on the health and safety of our professionals and those around us, we also are focused on continued service to our clients. We have taken steps to make sure we can continue to deliver the level of quality, excellence and timeliness you are accustomed to from us during these unique circumstances.

DRUGSCAN/DSI has long been committed to a flexible work place, and we have the technological, cultural and operational infrastructure for the organization to work virtually, should the need arise. Additionally, we have put into place policies that require all guests at DRUGSCAN/DSI offices and events to confirm that they do not pose a risk to others, based on certain criteria.

As we navigate this time of uncertainty together, I want to reaffirm our commitment to deliver actionable clinical insights that lead to therapies and treatments that provide health, healing and hope to patients around the world.

Sincerely,

Anthony Costantino, PhD, F- ABFT

President, DRUGSCAN